Aakash Desai Highlights GPT-4 as Clinical Decision Agent in Oncology
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:
“Major leap in oncology + AI! This isn’t your typical chatbot—it’s GPT-4 acting as a clinical decision agent.
What makes it different?
This AI doesn’t just respond, it acts:
- Segments CT scans (MedSAM)
- Detects histo-driven mutations (MSI, KRAS, BRAF)
- Pulls evidence from PubMed, OncoKB
- Synthesizes guideline-based treatment plans
Validated in a Nature Cancer study (Kather et al) with 20 simulated GI oncology cases:
- 87.2% treatment accuracy vs 30.3% using GPT-4 alone
- 91% factual accuracy, 75.5% guideline-aligned citations
- 87.5% autonomous tool use across imaging/path/genomics
Why this matters: We’re now seeing AI that doesn’t just suggest—it executes clinical reasoning start to finish.
Could this be the beginning of true autonomous oncology copilots?”
Title: Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology
Authors: Dyke Ferber, Omar S. M. El Nahhas, Georg Wölflein, Isabella C. Wiest, Jan Clusmann, Marie-Elisabeth Leßmann, Sebastian Foersch, Jacqueline Lammert, Maximilian Tschochohei, Dirk Jäger, Manuel Salto-Tellez, Nikolaus Schultz, Daniel Truhn, Jakob Nikolas Kather
Read The Full Article at Nature Cancer.
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023